BioPharmSignal logoBioPharmSignal

Biotech News

Oculis Publishes Invitation to the Annual General Meeting

Oculis (OCS)OculisCompany update

ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m.

Open original release

Related news

OCSOculis2026-05-05 08:00 EST

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

PRQRProQR Therapeutics2026-05-04 12:00 EST

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

SGHTSight Sciences2026-04-01 20:05 EST

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

OTLKOutlook2026-04-21 13:05 EST

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

OTLKOutlook2026-03-05 21:15 EST

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

View all latest news

Oculis

Oculis is an eye-disease company focused on ophthalmology therapies and topical or local delivery approaches. Its strategy is to build a differentiated eye-care franchise in high-value indications.

Recent company news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-05-14 20:05 EST

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

OCSOculis2026-05-11 20:07 EST

Oculis Reports Q1 2026 Financial Results and Provides Company Update

OCSOculis2026-05-07 08:58 EST

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

OCSOculis2026-05-05 08:00 EST

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Stock data

Close
11.06 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States